Olaparib plus bevacizumab provides significant clinical benefits and leads to substantial life-year and quality-adjusted life-year gain compared with bevacizumab among HRD-positive ovarian cancer patients.

Olaparib plus bevacizumab achieves clinical benefits with reasonable cost and provides good economic value as it is cost effective, compared with bevacizumab, for HRD-positive ovarian cancer patients.

Extrapolation methods accounting for long-term survivorship are important to capture the long-term clinical benefit associated with improved progression-free survival.

A biomarker-guided approach leads to optimal clinical outcomes with good economic value.